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Objective. This investigation was designed to assess the relationship between flow-mediated vasodilatation (FMD) and
nitroglycerin (NTG)-mediated vasodilatation (NMD) with atherosclerotic risk factors.
Methods. FMD and NMD were measured in 75 subjects including 57 patients with atherosclerotic disease (AAA/
PAOD¼ 30/27, age 72 7 years) and 18 controls. Brachial response to hyperemia and NTG were measured every minute
after cuff deflation and NTG administration.
Results. In the 75 subjects, responses to NTG showed a sigmoid curve. Only 2 cases reached maximal diameter within
4 minutes after NTG, and 90% of the cases reached maximal diameter at 6 minutes or later (7.5 2.0 minutes). In patients
with atherosclerotic disease, a multiple regression analysis showed higher FMD was associated with higher NMD, and
higher NMD was associated with smaller vessel size, lower systolic blood pressure, higher FMD, lower carotid maximal
IMT, lower serum levels of insulin, and lower HOMA-IR.
Conclusions. In subjects older than 54, NMD measured at 3 or 4 minutes after NTG administration would underestimate
the NTG-dependent vasodilatation. NMD measured with the maximal responded diameter was associated with atheroscle-
rotic risk factors, and it is therefore considered to be an important parameter in patients with atherosclerotic disease.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Both the smooth muscle and endothelium play a pivotal
role in atherosclerosis.1,2 Endothelial dysfunction is
considered to be an early event in atherosclerosis,
preceding ultrasonic evidence of atherosclerotic pla-
que.3 Numerous studies have documented impaired
brachial ultrasound assessment of endotheliume
dependent vasodilatation in the plaque-free peripheral
arteries of asymptomatic children and adults at risk for
atherosclerosis.4e6 This ultrasound study includes an
assessment of the vasodilatory response to nitrogly-
cerin (NTG), which acts directly at the level of the
arterial smooth muscle and produces an endothelium-
independent vasodilatation. Nitroglycerin-mediated
dilatation (NMD) has been used to check the vasodila-
tory responsiveness of smooth muscle, but the smooth
muscle function in itself has almost never been
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onstrated impaired NMD to be associated with a higher
systolic blood pressure,7 the presence of diabetes
mellitus,8 higher oxidized LDL, greater carotid IMT
and familial hypercholesterolemia.9
There have been few studies of NMD and FMD in
patients with peripheral arterial occlusive disease
(PAOD) and abdominal aortic aneurysm (AAA).10e14
We examined not only the magnitude but also the
time courses of the response to hyperemia and sublin-
gual NTG.
Methods
Subjects
We studied 57 patients with atherosclerotic disease
(AD) including 30 patients with AAA and 27 with
PAOD. The patients with PAOD had symptoms and
all patients came to our hospital for the purpose of re-
ceiving appropriate treatment. AAA was diagnosed
when a localized dilation of the abdominal aorta of
at least 50% or larger than an adjacent normal portionar Surgery. Published by Elsevier Ltd. All rights reserved.
640 D. Akamatsu et al.was detected by either ultrasonography or computed
tomography (CT). PAOD was diagnosed by duplex
scanning or CT based on an ABI< 0.90. No female
subjects were included in this study, because sexual
differences may confound the data analysis. The ex-
clusion criteria were decompensated heart failure,
malignant neoplasma, glaucoma, the need to receive
insulin therapy, ischemic gangrene, and evidence of
hepatic, renal or inflammatory disease.
The sex-matched 18 control adults included in the
study had an ABI> 0.9, normal electrocardiogram,
and normal ultrasonographic findings of the abdomi-
nal aorta to iliac artery.
Our institutional ethics committee approved the
study, and all participants gave their written informed
consent.
Data collection
All subjects were asked in detail regarding their med-
ical history, particularly regarding cardiovascular risk
factors, and any vascular events. After an overnight
fast a venous sample was taken, the plasma was sepa-
rated from the blood cells by centrifugation. The fast-
ing blood sugar (FBS) was measured enzymatically
(SRL, Tokyo, Japan). The serum insulin levels were
determined by a 2-step enzyme immunoassay (SRL,
Tokyo, Japan). The plasma total homocysteine was
analyzed by high-pressure liquid chromatography
(SRL, Tokyo, Japan). Plasma asymmetric dimethylar-
ginine (ADMA) was determined using high-pressure
liquid chromatography (SRL, Tokyo, Japan). The
serum concentration of advanced glycation end prod-
ucts (AGEs) was measured with an enzyme-linked
immunosorbent assay (SRL, Tokyo, Japan). The serum
adiponectin level was determined by an enzyme-
linked immunosorbent assay (SRL, Tokyo, Japan).
The serum CRP was measured with a highly sensitive
(hs) assay (Dade Bhering Diagnostics, Marburg,
Germany). The serum triglyceride, and total choles-
terol, HDL cholesterol, and LDL cholesterol levels
were all measured with commercially available kits.
A homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated using the following
formula: fasting plasma insulin (mU/ml) fasting
glucose (mmol/L)/22.5. As previously reported,15
HOMA-IR was validated in diabetic subjects treated
with diet therapy alone and in those treated with sul-
fonylureas. Atherosclerotic patients were studied by
Carotid ultrasound by 2 independent sonographers
blinded to the subject’s clinical details. In brief, bilat-
eral longitudinal scanning was performed from the
common carotid artery to the internal carotid artery.Eur J Vasc Endovasc Surg Vol 34, December 2007The scan was focused on the posterior (far) wall,
and performed in the optimal position. The maximal
thickness of intima-media complex (maxIMT) was
recorded and measured with electronic calipers.
Brachial ultrasound
After an overnight (14 hours) fast, changes in the
brachial diameter as a response to reactive hyperemia
and as a response to 300 mg of sublingual NTG
was measured using ultrasound (Aplio SSA-700A
5e12-MHz linear array transducer, Toshiba) as previ-
ously described.16 Vasoactive medications, such as
calcium antagonists, and b-blockers, ACE-inhibitors,
ARBs, and Nitrates were not administered for at least
14 hours. Caffeinated beverages and smoking were
not allowed on the day of the study. Briefly, the bra-
chial artery was scanned in longitudinal sections 2
to 10 cm above the elbow (control scan) after 15 min
of rest in the supine position. The depth and gain set-
tings were optimized to identify the anterior and pos-
terior intimal interfaces between the lumen and vessel
wall, and a baseline scan was recorded on super-VHS
for an offline analysis. Hyperemia was induced by
inflating and deflating a forearm blood pressure cuff
and it was inflated to 50 mmHg above the systolic
blood pressure for 5 minutes. The vasodilator res-
ponse to hyperemia was recorded for 5 minutes after
deflation. After at least 10 minutes rest, a further con-
trol scan was recorded. A single 300-mg dose of NTG
was sublingually administered. After the administra-
tion, we poured some water over the tablet and
looked into the mouth to see if the tablet was dissolv-
ing because in older patients dissolution may some-
times be delayed due to dentures or dryness of the
mouth.17 Thereafter, the vasodilator response to
NTG was recorded for 15 minutes. NTG was omitted
if the subjects either refused it, had a systolic blood
pressure of <100 mm Hg, or a previous adverse reac-
tion to nitrates.
Measurements were taken at end-diastole, coinci-
dent with the R-wave on ECG, every one minute after
deflation or after the administration of NTG. The arte-
rial diameter was analyzed for three cardiac cycles,
and then these measurements were averaged. The
diameter responded to reactive hyperemia and NTG
was expressed as a percent change relative to the dia-
meter immediately before cuff inflation and relative
to the diameter immediately before drug administra-
tion, respectively. The same operator, who was
blinded to the details of subjects’ data, studied all
brachial ultrasound images. In our laboratory, the
intraobserver variability for repeated measurements
641Smooth Muscle Dysfunction in Patientsof resting arterial diameter was 0.02 0.01 mm, for
FMD was 0.49 0.27 (%), and for NMD was
0.44 0.34 (%), respectively.
Brachial IMT was measured as previously
described.9 The same segment of the brachial artery
for the analysis of vasodilator response was measured
for brachial IMT. The scan was focused on the
posterior wall, and 8 measurements were taken at
end-diastole, coincident with the R-wave, at even
intervals. The average of these measurements was
used as the mean brachial IMT in the analysis.
Statistical analysis
All descriptive data were expressed as the mean SD.
A comparison for continuous variables between the
groups was made by either an Analysis of covariance
(ANCOVA), the t-test or the Mann-Whitney test. Cat-
egorial variables were compared with either the c2
test or Fisher’s exact probability test. Univariate asso-
ciations between the study variables were analyzed
by calculating the Pearson’s correlation coefficient. A
multiple stepwise regression analysis was used to
assess which variables were significantly related to
FMD or NMD. In the regression models, we first
assessed the presence of a univariate correlation
between the variables and FMD or NMD. The vari-
ables were then entered into the model based on the
selection criteria of P< 0.10. A P value of less than
0.05 was considered to be significant. All statistical
analyses were performed using the Stat View 5.0
statistical analysis software program.
Results
All 75 subjects underwent the FMD evaluation, but 2
AD patients refused to take NTG. In the present
study, the AD patients were significantly older than
control subjects (72 7 years, range 54 to 86 versus
69 3 years, range 65 to 75, p¼ 0.013). Therefore,
a comparison of continuous variables between two
groups was made by ANCOVA while adjusting for
age. In comparison to the control subjects, the AD pa-
tients had a lower FMD (2.11.7 versus 3.3 2.3%,
p¼ 0.014) but a similar NMD (17.9 7.2 versus
18.1 6.6%, p¼ 0.918). The NMD measured at 3 min-
utes after administration (NMD3) was lower in the
AD patients but the difference was not statistically
significant (7.6 5.2 versus 10.4 6.8%, p¼ 0.070).
The characteristics of the subjects are shown in Tables
1 and 2.
In the AD group, FMD and NMD and NMD3 were
similar between the patients with AAA and PAOD.Time course of the brachial artery response in this study
In the 57 AD patients, the response to hyperemia
reached a maximal diameter at 1.3 0.6 minutes
post-deflation (1 min e 42 cases, 2 min e 13 cases,
3 min e 1 case, 4 min e 1case). While in the control
subjects the response to hyperemia reached a maximal
diameter at at 1.1 0.2 minutes (1 min e 17 cases, 2
min e 1 case). The time courses of response to NTG
are shown in Figs. 1 and 2. In the AD patients and
control subjects the brachial artery reached a maximal
diameter at 7.6 2.2 (range 4 to 13) and 7.1 0.9
(range 5 to 8) minutes post-NTG administration,
Table 1
Control (N¼ 18) Patients (N¼ 57)
Age (y) 69 3 72 7*
Sex (M/F) 18/0 57/0
Body mass index (kg/m2) 24.8 2.2 23.3 3.1
Coronary artery disease 0 (0) 16 (28)*
Cerebrovascular disease 0 (0) 7 (12)
Hypertension 3 (17) 46 (80)*
Hyperlipidemia 3 (17) 20 (35)
Diabetes mellitus 2 (11) 13 (23)
IGT 7 (34) 16 (28)
Smoking (pack-year) 1.9 4.8 52 28*
Treatment
ACE inhibitors 0 20 (35)*
Calcium antagonists 0 39 (68)*
ARBs 0 15 (26)*
Nitrates 0 12 (21)
Statins 0 9 (16)
Cilostazol 0 11 (19)
Ticlopidine hydrochloride 0 5 (9)
Aspirin 0 16 (28)*
Oralhypoglycemic agents 0 5 (9)
The numbers in parentheses represent the percentages.
*P < .05 vs control subjects.
Table 2
Control (N¼ 18) Patients (N¼ 57)
Systolic BP (mm Hg) 128 17 138 24
Diastolic BP (mm Hg) 82 10 81 11
Total cholesterol (mmol/L) 4.92 0.80 5.07 0.88
LDL cholesterol (mmol/L) 2.84 0.64 3.23 0.64*
HDL cholesterol (mmol/L) 1.24 0.28 1.13 0.36
Triglycerides (mmol/L) 1.15 0.62 1.37 0.75
hs-CRP (mg/L) 1.16 1.48 2.78 3.48
ADMA (nmol/mL) 0.47 0.05 0.47 0.09
Total homocysteine (nmol/mL) 9.7 2.1 13 3.6*
AGEs (mU/ml) 2.46 0.52 2.82 0.62*
Fasting blood sugar (mmol/L) 5.10 0.52 6.04 1.27*
insulin (mU/mL) 3.82 2.41 8.41 6.45*
HOMA-R 0.88 0.60 2.24 1.80*
Adiponectin (mg/mL) 9.74 5.80 10.39 5.11
Brachial IMT (mm) 0.41 0.08 0.46 0.06*
Brachial artery diameter (mm) 4.5 0.6 4.3 0.7
*P < .05 vs control subjects.Eur J Vasc Endovasc Surg Vol 34, December 2007
642 D. Akamatsu et al.respectively. The time courses showed a sigmoid
curve, a gradual increase from 0 to 2 minutes and
a rapid increase from 2 to about 5 minutes, followed
again by a gradual increase. In the 73 cases, only two
cases (2.7%) reached a maximal diameter at 4 minutes
post-NTG administration, while 66 cases (90.4%) did
so at 6 minutes or later.
FMD and atherosclerotic risk factors in patients
with atherosclerotic disease
According to a univariate analysis, the FMD in the
57 patients was inversely correlated with the vessel
size, SBP, HOMA-IR, and it was directly and closely
correlated with the maximal NMD (Fig. 3). In a mul-
tiple stepwise regression analysis, the serum levels of
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Fig. 1. The time courses of the brachial artery response to
NTG in patients with atherosclerotic disease. The time
courses showed a sigmoid curve. Only 2 patients reached
maximal diameter within 4 minutes after administration.
The figure shows the curves for only 55 cases because 2
cases refused to take the NTG tablets.
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Fig. 2. The time courses of the brachial artery response to
NTG in control subjects. Control subjects also showed a sig-
moid curve. The figure shows the curves of 16 cases because
we failed to identify both of intimal interfaces at one to two
points of measurements in 2 cases (Case 1 failed to identify
NMD2 and NMD4. Case 2 failed NMD2).Eur J Vasc Endovasc Surg Vol 34, December 2007insulin and brachial IMT (p< 0.1) were included in
the model in addition to the above 4 parameters,
and either insulin or HOMA-IR was separately in-
cluded in the model because insulin correlated very
closely with HOMA-IR (r¼ 0.979, p< 0.001). The in-
dependent determinant of FMD was the NMD. No
other parameter was independently associated with
FMD (Table 3). The squared multiple correlation co-
efficient adjusted for the degree of freedom (R2) was
0.447 when HOMA-IR was included in the model,
and 0.375 when serum levels of insulin was
included.
NMD and atherosclerotic risk factors
in patients with atherosclerotic disease
According to a univariate analysis, the NMD in the 55
patients was inversely correlated with the vessel size,
smoking status, SBP, total cholesterol, serum levels of
insulin, HOMA-IR, and it was also directly correlated
with FMD. A multiple stepwise regression analysis in-
cluded the brachial IMT (p< 0.1) and carotid maxIMT
(p< 0.1). In a multivariate model, FMD, SBP, vessel
size, carotid maxIMT, serum levels of insulin and
HOMA-IR were independently associated with
NMD (Table 3). R2 was 0.754 when HOMA-IR was
included in the model and 0.714 when insulin was
included.
NMD3 was associated with FMD and the vessel
size, though, no other association was demonstrated
between NMD3 and risk factors.
Similar results were obtained when patients using
hypoglycemic agents were excluded.
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Fig. 3. Correlation between the flow-mediated vasodilata-
tion (FMD) and the NTG-mediated vasodilatation (NMD)
in patients with atherosclerotic disease. FMD was directly
and closely correlated with NMD (n¼ 55).
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Univariate Multivariate
r p b p
FMD
NMD 0.630 <0.001 0.676 (0.622) <0.001 (<0.001)
vessel size 0.445 <0.001 e 0.803 (0.351)
brachial IMT 0.229 0.090 e 0.522 (0.388)
HOMA-R 0.264 0.049 e 0.422
insulin 0.243 0.068 e (0.450)
SBP 0.364 0.005 e 0.543 (0.464)
NMD
vessel size 0.551 <0.001 0.443 (0.415) <0.001 (<0.001)
SBP 0.468 <0.001 0.418 (0.465) <0.001 (<0.001)
FMD 0.630 <0.001 0.316 (0.241) <0.001 (0.016)
maxIMT 0.249 0.084 0.210 (0.269) 0.007 (0.001)
HOMA-R 0.292 0.032 0.194 0.027
insulin 0.271 0.044 (0.236) (0.012)
Smoking status 0.268 0.049 e 0.305 (0.258)
Total cholesterol 0.283 0.041 e 0.311 (0.388)
brachial IMT 0.227 0.099 e 0.798 (0.650)
The numbers in parentheses indicate standard regression coefficient and p value when insulin was included in the model.Discussion
The present study demonstrated a close correlation
between FMD, the endothelium-dependent vaso-
dilatory response, and NMD, the smooth muscle-
dependent response, in patients with atherosclerotic
disease. The only independent determinant of FMD
was NMD on a multiple stepwise regression analysis.
Independent determinants of impaired maximal
NMD included a larger vessel size, higher SBP, lower
FMD, increased carotid maxIMT, increased serum
levels of insulin, and higher HOMA-IR. We are aware
of no published reports that have described the asso-
ciations between smooth muscle-dependent vasodila-
tation and risk factors in patients with atherosclerotic
disease. Most of the studies measuring the vasodilator
response induced by a single high dose of NTG at 3e4
minutes did not show any association with risk fac-
tors. We measured the vasodilator response every
minute after administration, although previous re-
ports recommended subplateau doses of NTG.9,18 Us-
ing this method, we detected the maximal diameter
induced by a single dose of NTG. It is generally
thought that NTG has a plasma half-life of 3 minutes
and peak plasma concentrations occurs at 4 to 5 min-
utes.19 As a result, most observers recommend mea-
surements at 3 to 4 minutes after administration.16
In the present study, the time courses of the vasodila-
tory response to NTG showed a sigmoid curve, and
90% of the subjects showed a maximal diameter after
6 minutes or later. The reason for this discrepancy was
not because of dentures or of dryness of the mouth,
but because pharmacodynamic or pharmacokineticchanges of NTG tend to be delayed in elderly sub-
jects.19 Alternatively, hypertension, insulin resistance
or some other risk factors unidentified in this study
may also have delayed NMD. Therefore, at least
in subjects older than 54 years of age, measuring the
diameter at 3 or 4 minutes post-NTG may underesti-
mate the smooth muscle function, and observers
should therefore take measurements at least 6 minutes
or later when performing one point measurements.
In theory the brachial ultrasound test for endothelial
function is a method measuring the relaxing effect of
the smooth muscle induced by endothelium-derived
endogenous nitric oxide (NO). For that reason, FMD
should be considered a parameter including function
of the endothelium and of smooth muscle and it would
be important to evaluate smooth muscle function.
A question remains regarding whether an impaired
dilator response to NTG might be due to mechanical
forces limiting the artery’s ability to relax or due to
a decreased use of NTG inside the smooth muscle.
To explain whether mechanical forces limited the vas-
odilatory response or not, we measured the brachial
IMT, although we performed brachial ultrasound in
an artery without any plaques. The brachial IMT did
not significantly correlate with NMD, nor was any
association observed based on a multiple regression
analysis. Hence, the likely explanation for our finding
is a decreased use of NTG inside the smooth muscle,
i.e. smooth muscle dysfunction.
Our data demonstrated a higher FMD, a higher
SBP, higher serum levels of insulin, and a higher
HOMA-IR to be independently associated with an im-
paired NMD. The reason why FMD was involved inEur J Vasc Endovasc Surg Vol 34, December 2007
644 D. Akamatsu et al.NMD was not because endothelial function affected
NTG mediated vasodilatation. NTG causes a slight in-
crease in the brachial flow20 but such a low stimulus
would not evoke NO production in patients with seri-
ously attenuated endothelial function. The mecha-
nisms responsible for smooth muscle dysfunction
remain speculative. Various mechanisms may be
involved in the vascular dysfunction in complicated
patients. Our speculation is that a decrease in the
bioactivation of NTG by enzymes such as mtALDH
(described by Chen et al.21) may be a possible mecha-
nism in the development of smooth muscle dysfunc-
tion. Measuring the vasodilatory response to sodium
nitroprusside, a direct stimulator of soluble guanylate
cyclase, may thus help to explain whether an attenu-
ated bioactivation of NTG is present or not.
Recently, some observers have indicated the pre-
dictive value of FMD for cardiovascular events in
PAOD.22,23 Although NMD was not an independent
predictor of event in those reports, this does not
mean that NMD had no association with the clinical
outcome because NMD was measured at 3 minutes
after NTG administration. NMD was therefore likely
underestimated.
Our study has some limitations. First, although it
remains controversial regarding whether atheroscle-
rosis is a causative factor in aneurysms,24 we in-
cluded patients with AAA in the atherosclerotic
disease group because most patients with AAA ex-
hibit risk factors for atherosclerosis, manifestations
of coronary or cerebrovascular disease1,25 and ultra-
sonographic evaluation of FMD, NMD, NMD3 were
similar between AAA and PAOD. Second, our sam-
ple size was limited and additional large-scale exper-
imental studies are needed to explain the causal
relationships between risk factors and an impaired
vascular function. Third, although medication was
discontinued for at least 14 hours before study, we
cannot rule out the possibility that the long-acting
effect of drugs may have beneficially influenced
the FMD and NMD in the AD patients. However,
long-term drug discontinuation is difficult both
therapeutically and ethically.
In conclusion, in patients with AAA and PAOD,
the vasodilatory response to exogenous NO was asso-
ciated with FMD, SBP, the serum levels of insulin,
HOMA-IR and carotid maxIMT. FMD was only asso-
ciated with NMD. Regarding the value of an ultra-
sound test for patients with objective evidence of
atherosclerotic disease, not only FMD but also NMD
may be an important marker. A large-scale study eval-
uating the association between NMD measured with
a maximal responded diameter and clinical outcome
is thus called for.Eur J Vasc Endovasc Surg Vol 34, December 2007Acknowledgments
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